181 related articles for article (PubMed ID: 24891169)
21. Prognostic factors in mortality and morbidity in patients with differentiated thyroid cancer.
Witt RL; McNamara AM
Ear Nose Throat J; 2002 Dec; 81(12):856-63. PubMed ID: 12516384
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
23. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer.
Cross S; Wei JP; Kim S; Brams DM
J Surg Oncol; 2006 Dec; 94(8):678-82. PubMed ID: 17131414
[TBL] [Abstract][Full Text] [Related]
24. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
25. Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy.
Verburg FA; Luster M
Minerva Chir; 2010 Feb; 65(1):95-100. PubMed ID: 20212421
[TBL] [Abstract][Full Text] [Related]
26. [Radical surgical treatment of differentiated thyroid cancer--necessity or over-enthusiasm?].
Nowak W; Szybiński P
Wiad Lek; 2001; 54 Suppl 1():189-97. PubMed ID: 12182024
[TBL] [Abstract][Full Text] [Related]
27. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.
Links TP; van Tol KM; Jager PL; Plukker JT; Piers DA; Boezen HM; Dullaart RP; de Vries EG; Sluiter WJ
Endocr Relat Cancer; 2005 Jun; 12(2):273-80. PubMed ID: 15947102
[TBL] [Abstract][Full Text] [Related]
28. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
29. Update on recent developments in the therapy of differentiated thyroid cancer.
Middendorp M; Grünwald F
Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
31. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma.
Untch BR; Palmer FL; Ganly I; Patel SG; Michael Tuttle R; Shah JP; Shaha AA
Ann Surg Oncol; 2014 Apr; 21(4):1374-8. PubMed ID: 24366419
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.
Lin JD; Chao TC; Hsueh C
Clin Endocrinol (Oxf); 2007 Feb; 66(2):224-8. PubMed ID: 17223992
[TBL] [Abstract][Full Text] [Related]
33. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
34. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
35. [Differentiated thyroid cancer--staging and prognostic systems].
Dănilă R; Andriescu L; Grigorovici A; Dragomir C; Găluşcă B; Vulpoi C; Ungureanu C; Mogoş V
Rev Med Chir Soc Med Nat Iasi; 2005; 109(1):71-6. PubMed ID: 16607831
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
37. Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma.
Orlov S; Orlov D; Shaytzag M; Dowar M; Tabatabaie V; Dwek P; Yip J; Hu C; Freeman JL; Walfish PG
Head Neck; 2009 Jun; 31(6):782-8. PubMed ID: 19260133
[TBL] [Abstract][Full Text] [Related]
38. Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.
Passler C; Prager G; Scheuba C; Kaserer K; Zettinig G; Niederle B
Ann Surg; 2003 Feb; 237(2):227-34. PubMed ID: 12560781
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
40. Radioactive iodine therapy.
Lee SL
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):420-8. PubMed ID: 22914564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
